Genetic Research as Therapy: Implications of “Gene Therapy” for Informed Consent
- 1 January 1998
- journal article
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- Vol. 26 (1) , 38-47
- https://doi.org/10.1111/j.1748-720x.1998.tb01904.x
Abstract
In March 1996, the General Accounting Office (GAO) issued the report Scientific Research: Continued Vigilance Critical to Protecting Human Subjects. It stated that “an inherent conflict of interest exists when physician-researchers include their patients in research protocols. If the physicians do not clearly distinguish between research and treatment in their attempt to inform subjects, the possible benefits of a study can be overemphasized and the risks minimized.” The report also acknowledged that “the line between research and treatment is not always clear to clinicians. Controversy exists regarding whether certain medical procedures should be categorized as research.” This problem currently plagues gene transfer research. A few months prior to the GAO report, an ad hoc committee appointed by National Institutes of Health (NIH) Director Harold Varmus expressed similar concerns in its assessment of NIH investment in research on gene therapy.Keywords
This publication has 22 references indexed in Scilit:
- The TMC Worldwide Gene Therapy Enrollment Report, End 1996. Report of TMC Development, Paris, FranceHuman Gene Therapy, 1997
- Adversarios admirablesHispania, 1997
- Gene Therapy in the United States: A Five-Year Status ReportHuman Gene Therapy, 1996
- Commentary: Examining the Ethics of Human Subjects ResearchKennedy Institute of Ethics Journal, 1996
- PredictionAutoimmunity, 1996
- Overregulation Is an Unnecessary Hindrance to Human Gene TherapyHuman Gene Therapy, 1995
- Regulation of Human Gene TherapyScience, 1995
- One Less Hoop for Gene TherapyScience, 1994
- ADA Gene Therapy Enters the CompetitionScience, 1990
- Human Gene Therapy: Part of a Therapeutic ContinuumHuman Gene Therapy, 1990